Anti-Inflammatory Drug for Heart Disease
By Biotechdaily staff writers
Posted on 14 Mar 2003
An experimental drug that represents a new class of anti-inflammatory proteins is under investigation for the treatment of acute coronary syndrome.Posted on 14 Mar 2003
The first human trial of this anti-inflammatory protein, VT-111, has been successfully completed by the developer, Viron Therapeutics, Inc. (London, Canada). The trial assessed tolerability, safety, and pharmacokinetic properties. Currently, there are no anti-inflammatory drugs on the market that have been approved for the treatment of heart disease. Viron seeks to take advantage of this sizeable market opportunity.
"Viron is excited about the continued success of its lead compound VT-111,” said Mark Poznansky, president and CEO of Viron. "It is becoming increasingly clear that inflammation is a bigger predictor of heart attacks than even cholesterol.” Viron is a biotechnology company focused on the discovery and development of novel protein therapeutics for the treatment of human disease. The company was spun off from Robarts Research Institute (London, Canada).
Related Links:
Viron
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
